HK1247046A1 - 用於過繼性t細胞療法的中央記憶t細胞 - Google Patents

用於過繼性t細胞療法的中央記憶t細胞

Info

Publication number
HK1247046A1
HK1247046A1 HK18106866.8A HK18106866A HK1247046A1 HK 1247046 A1 HK1247046 A1 HK 1247046A1 HK 18106866 A HK18106866 A HK 18106866A HK 1247046 A1 HK1247046 A1 HK 1247046A1
Authority
HK
Hong Kong
Prior art keywords
adoptive
cells
cell therapy
central memory
memory
Prior art date
Application number
HK18106866.8A
Other languages
English (en)
Inventor
Christine E Brown
Stephen J Forman
Original Assignee
希望之城公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1247046(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 希望之城公司 filed Critical 希望之城公司
Publication of HK1247046A1 publication Critical patent/HK1247046A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464419—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK18106866.8A 2014-09-19 2018-05-25 用於過繼性t細胞療法的中央記憶t細胞 HK1247046A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462053068P 2014-09-19 2014-09-19
PCT/US2015/051280 WO2016044853A1 (en) 2014-09-19 2015-09-21 Central memory t cells for adoptive t cell therapy

Publications (1)

Publication Number Publication Date
HK1247046A1 true HK1247046A1 (zh) 2018-09-21

Family

ID=55533940

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106866.8A HK1247046A1 (zh) 2014-09-19 2018-05-25 用於過繼性t細胞療法的中央記憶t細胞

Country Status (16)

Country Link
US (3) US9914909B2 (zh)
EP (4) EP3587446A1 (zh)
JP (7) JP6657195B2 (zh)
KR (3) KR20170057351A (zh)
CN (4) CN107002084B (zh)
AU (4) AU2015317351B2 (zh)
BR (3) BR112017005631A2 (zh)
CA (2) CA2961654A1 (zh)
DK (1) DK3200591T3 (zh)
ES (2) ES2738705T3 (zh)
HK (1) HK1247046A1 (zh)
IL (6) IL308324A (zh)
MX (4) MX2017003596A (zh)
NZ (1) NZ730208A (zh)
RU (2) RU2749922C2 (zh)
WO (2) WO2016044811A1 (zh)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
CN107002084B (zh) * 2014-09-19 2021-09-10 希望之城公司 靶向IL13Rα2的共刺激嵌合抗原受体T细胞
FI3298033T4 (fi) 2015-05-18 2023-09-22 Tcr2 Therapeutics Inc Koostumuksia ja lääkinnällisiä käyttöjä fuusioproteiineja käyttävälle tcr:n uudelleenohjelmoinnille
AU2016301932B2 (en) * 2015-08-05 2020-02-27 CellabMED Inc. Chimeric antigen receptor, and T cells in which chimeric antigen receptor is expressed
AU2017240667C1 (en) 2016-04-01 2022-11-24 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
CN116425876A (zh) 2016-04-01 2023-07-14 凯德药业股份有限公司 Bcma结合分子及其使用方法
WO2017173410A1 (en) * 2016-04-01 2017-10-05 Amgen Inc. Chimeric receptors to flt3 and methods of use thereof
KR20200068750A (ko) 2016-04-01 2020-06-15 카이트 파마 인코포레이티드 키메라 수용체 및 그의 사용 방법
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
AU2017276706A1 (en) * 2016-06-07 2019-01-03 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
AU2017279548A1 (en) * 2016-06-08 2018-12-13 Precigen, Inc. Cd33 specific chimeric antigen receptors
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
AU2017326173B2 (en) * 2016-09-16 2022-08-18 Baylor College Of Medicine Platform for activation and expansion of virus-specific T-cells
AU2017341048A1 (en) 2016-10-07 2019-05-23 TCR2 Therapeutics Inc. Compositions and methods for T-cell receptors reprogramming using fusion proteins
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
WO2018102761A1 (en) 2016-12-02 2018-06-07 City Of Hope Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors
WO2018106972A1 (en) * 2016-12-07 2018-06-14 La Jolla Institute For Allergy And Immunology Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
CN108395481B (zh) * 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定
US20200061114A1 (en) * 2017-02-22 2020-02-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Il13ra2-binding chimeric antigen receptors
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
AU2018242408B2 (en) * 2017-03-27 2022-08-04 Noile-Immune Biotech, Inc. Chimeric antigen receptor
EP3612210A4 (en) * 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System IMMUNE CELLS EXPRESSING MODIFIED ANTIGEN RECEPTORS
CN107267555B (zh) * 2017-05-27 2020-03-20 上海优卡迪生物医药科技有限公司 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用
JP7391831B2 (ja) * 2017-08-11 2023-12-05 シティ・オブ・ホープ Ｃａｒ ｔ細胞標的を発現する腫瘍溶解性ウイルス、及びその使用
EP3704156A1 (en) * 2017-11-03 2020-09-09 Sorrento Therapeutics, Inc. Cd38-directed chimeric antigen receptor constructs
CN109971712B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
CN109971721B (zh) * 2017-12-28 2023-10-31 上海细胞治疗研究院 自表达cd47抗体的间皮素特异性car-t细胞及其用途
CA3089051A1 (en) 2018-01-22 2019-07-25 Endocyte, Inc. Methods of use for car t cells
US20200354477A1 (en) * 2018-02-06 2020-11-12 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
AU2019218989A1 (en) * 2018-02-12 2020-08-27 The General Hospital Corporation Chimeric antigen receptors targeting the tumor microenvironment
JP7438123B2 (ja) * 2018-03-14 2024-02-26 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 腫瘍特異的Ｔ細胞免疫療法用のＩＬ－１３受容体α２（ＩＬ１３Ｒα２）標的キメラ抗原受容体
EA202091984A1 (ru) * 2018-03-14 2021-02-18 Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) Направленная дзетакинами т-клеточная иммунотерапия, нацеленная на рецептор il-13 альфа 2
EP3797164A4 (en) * 2018-05-21 2022-03-02 Biosceptre (Aust) Pty Ltd CHEMERA ANTIGEN RECEPTORS WITH MODIFIED BINDING DOMAINS AND USES THEREOF
CA3102097A1 (en) * 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior Unversity Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
AU2019295855A1 (en) 2018-06-29 2021-01-28 City Of Hope CD6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders
EP3834833A4 (en) * 2018-08-10 2022-05-18 Eutilex Co., Ltd. TUMOR ANTIGEN-SPECIFIC CYTOTOXIC T CELLS
WO2020191336A1 (en) 2019-03-21 2020-09-24 Yamaguchi, Yukiko Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl
WO2020205751A1 (en) 2019-03-29 2020-10-08 City Of Hope Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
WO2021004400A1 (zh) * 2019-07-06 2021-01-14 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
CN112204135A (zh) * 2019-07-06 2021-01-08 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
EP3769816A1 (en) * 2019-07-25 2021-01-27 Ospedale Pediatrico Bambino Gesù Car-cd123 vector and uses thereof
WO2021138454A1 (en) 2019-12-30 2021-07-08 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
US20230374085A1 (en) * 2020-03-11 2023-11-23 City Of Hope Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatment
CN115515971A (zh) * 2020-03-12 2022-12-23 希望之城公司 治疗IL13Rα2阳性恶性病的靶向性嵌合抗原受体修饰的T细胞
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
KR20230121993A (ko) * 2020-09-10 2023-08-22 무스탕 바이오, 인크. 암 표적 car-t 세포를 포함하는 병용 요법 및 암 치료를 위한 이의 사용 방법
US20230364138A1 (en) 2020-11-23 2023-11-16 City Of Hope Engineered t cells for expression of chimeric anitgen receptors
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
CN114907485B (zh) * 2021-02-08 2024-04-26 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
US20240158521A1 (en) * 2021-03-18 2024-05-16 The Wistar Institute Of Anatomy And Biology DNA-ENCODED BISPECIFIC ANTIBODIES TARGETING IL13Ra2 AND METHODS OF USE IN CANCER THERAPEUTICS
CN117242090A (zh) 2021-03-30 2023-12-15 希望之城公司 CAR T细胞疗法和IFNγ
US20230190799A1 (en) * 2021-07-21 2023-06-22 City Of Hope Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
CN113621077B (zh) * 2021-09-02 2023-01-31 山东大学 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞
EP4176895A1 (en) * 2021-11-08 2023-05-10 AvenCell Europe GmbH Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor
WO2023130462A1 (zh) * 2022-01-10 2023-07-13 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的嵌合抗原受体及其用途
CN115960257B (zh) * 2022-09-29 2023-10-27 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的经优化的嵌合抗原受体及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
ATE297986T1 (de) * 1995-02-24 2005-07-15 Gen Hospital Corp Neuorientierung der zellulären immunität durch rezeptorchimären
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US6576232B1 (en) 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
EP1100529B2 (en) 1998-07-30 2010-08-25 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Thymosin beta 4 promotes wound repair
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
US7560280B2 (en) 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
CA2445746C (en) 2001-04-30 2012-09-18 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7514537B2 (en) * 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US11278594B2 (en) * 2001-04-30 2022-03-22 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
ATE373904T1 (de) 2003-07-24 2007-10-15 Matsushita Electric Ind Co Ltd Verfahren, kodierer und kommunikationsvorrichtung zur kodierung von parallel verketteten daten
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
US7754441B2 (en) * 2003-11-17 2010-07-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
DE102004043271A1 (de) * 2004-09-07 2006-03-09 Linde Ag Verfahren zur Synthese von Zirkoniumcarboxylaten
PT1814580T (pt) * 2004-11-24 2016-11-11 Hutchinson Fred Cancer Res Métodos de utilização de il-21 para imunoterapia adotiva e identificação de antigénios tumorais
CN101346463B (zh) * 2005-12-21 2012-06-13 江苏太瑞生诺生物医药科技有限公司 用于癌患者免疫治疗的瘤反应性t-淋巴细胞扩增的改善方法
CA2634072A1 (en) * 2005-12-21 2007-06-28 Universite De Montreal Markers for memory t cells and uses thereof
LT2126054T (lt) 2007-01-31 2016-10-10 Yeda Research And Development Company Limited Peradresuotos, genetiškai modifikuotos t reguliavimo ląstelės ir jų naudojimas autoimuninės ir uždegiminės ligos slopinimui
CN101842387B (zh) * 2007-09-26 2014-05-07 Ucb医药有限公司 双特异性抗体融合物
CA2735456C (en) * 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
CA2785139A1 (en) * 2009-12-22 2011-06-30 Novartis Ag Tetravalent cd47-antibody constant region fusion protein for use in therapy
GB2481983A (en) * 2010-07-12 2012-01-18 Hart Fenton & Co Ltd A ship including a gas tank room
EP2606124A1 (en) * 2010-08-18 2013-06-26 The U.S.A. as represented by the Secretary, Department of Health and Human Services Methods of identifying central memory t cells and obtaining antigen-specific t cell populations
EP3305798A1 (en) * 2010-12-09 2018-04-11 The Trustees of The University of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN106074601A (zh) * 2011-03-23 2016-11-09 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
EP2532740A1 (en) * 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
EP3594245A1 (en) * 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
RU2019126655A (ru) * 2012-08-20 2019-11-12 Фред Хатчинсон Кансэр Рисёч Сентер Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
CN107002084B (zh) 2014-09-19 2021-09-10 希望之城公司 靶向IL13Rα2的共刺激嵌合抗原受体T细胞

Also Published As

Publication number Publication date
EP3200591B1 (en) 2021-03-31
IL251188A0 (en) 2017-05-29
IL292828A (en) 2022-07-01
IL292650B1 (en) 2023-12-01
KR20230169455A (ko) 2023-12-15
BR112017005630A2 (pt) 2018-06-26
AU2020203651A1 (en) 2020-06-25
RU2763523C2 (ru) 2021-12-30
NZ730208A (en) 2024-03-22
EP3916084A1 (en) 2021-12-01
JP2023052506A (ja) 2023-04-11
JP7171871B2 (ja) 2022-11-15
ES2876235T3 (es) 2021-11-12
RU2749922C2 (ru) 2021-06-21
JP6657195B2 (ja) 2020-03-04
CA2961676A1 (en) 2016-03-24
EP3200591A1 (en) 2017-08-09
IL280576A (en) 2021-03-25
MX2021012720A (es) 2022-01-06
KR20170057351A (ko) 2017-05-24
US20160340649A1 (en) 2016-11-24
CN107404881A (zh) 2017-11-28
IL280576B (en) 2022-06-01
DK3200591T3 (da) 2021-06-21
JP2017534262A (ja) 2017-11-24
BR112017005631A2 (pt) 2018-06-26
AU2024201326A1 (en) 2024-04-11
CN113637640A (zh) 2021-11-12
EP3194433A1 (en) 2017-07-26
US20180265844A1 (en) 2018-09-20
CN107002084A (zh) 2017-08-01
RU2017111300A (ru) 2018-10-19
EP3200591A4 (en) 2018-04-04
IL251196A0 (en) 2017-05-29
IL251188B (en) 2022-07-01
AU2015317351B2 (en) 2020-07-02
IL251196B (en) 2021-02-28
IL292650A (en) 2022-07-01
KR102610715B1 (ko) 2023-12-08
JP2023014100A (ja) 2023-01-26
RU2017111300A3 (zh) 2019-09-04
US20200318069A1 (en) 2020-10-08
US10676717B2 (en) 2020-06-09
CA2961654A1 (en) 2016-03-24
EP3194433B1 (en) 2019-05-22
CN107002084B (zh) 2021-09-10
JP6711819B2 (ja) 2020-06-17
EP3587446A1 (en) 2020-01-01
IL308324A (en) 2024-01-01
KR20170054509A (ko) 2017-05-17
JP2017529081A (ja) 2017-10-05
WO2016044853A8 (en) 2017-04-06
JP2020100626A (ja) 2020-07-02
WO2016044853A1 (en) 2016-03-24
AU2015317351A1 (en) 2017-04-06
JP6986190B2 (ja) 2021-12-22
JP2020156494A (ja) 2020-10-01
JP2022017333A (ja) 2022-01-25
MX2017003557A (es) 2017-10-12
WO2016044811A1 (en) 2016-03-24
BR122024000360A2 (pt) 2024-02-27
CN113789336A (zh) 2021-12-14
BR112017005630B1 (pt) 2023-12-12
MX2021006400A (es) 2021-07-15
RU2017111298A (ru) 2018-10-19
JP7216045B2 (ja) 2023-01-31
RU2017111298A3 (zh) 2019-03-13
CN107404881B (zh) 2021-07-09
ES2738705T3 (es) 2020-01-24
US9914909B2 (en) 2018-03-13
MX2017003596A (es) 2017-10-20
IL292650B2 (en) 2024-04-01
AU2021277651A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
IL292828A (en) Central memory t cells for t cell stress therapy
IL292504B1 (en) Methods of preparing t cells for t cell therapy
HK1255161A1 (zh) 用於過繼性細胞治療的工程細胞
IL276593B (en) Improved methods for producing adoptive cell therapies
IL250072A0 (en) Transgenic cells for stress cell therapy
HK1244826A1 (zh) 用於過繼細胞治療的方法和組合物
IL249424A0 (en) nk-92 cells expressing car as cell therapy factors
EP3370743A4 (en) METHODS OF PREPARING LYMPHOCYTES FOR ADOPTIVE TRANSFER THERAPY OF T-CELLS
IL249506A0 (en) Hybrid electrochemical cell
SG11201703493SA (en) Cell culture insert
PL3134724T3 (pl) Komórka elektrochemiczna
HUP1400380A2 (hu) Napelem cella elrendezés
DK3365432T3 (en) Stem cell therapy based on adipose-derived stem cells
HK1250931A1 (zh) 誘導有絲分裂期後細胞的細胞分裂的方法
GB201522223D0 (en) Therapeutic T cells
EP3936188C0 (en) CELLS FOR REGENERATIVE THERAPY
GB2551997B (en) Battery cell arrangement
GB2539233B (en) Electrochemical cell
AU2015902675A0 (en) Adoptive t cell therapy
PL3128579T3 (pl) Ogniwo baterii
GB201521571D0 (en) Electrochemical cell
GB201411798D0 (en) Electrochemical cell
GB201510142D0 (en) Electrochemical cells
GB201421342D0 (en) Cell culture
GB201403622D0 (en) Mammalian cell storage medium